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Abstract 
Intrinsically disordered proteins have been shown to be important in many physiological 
processes, including cell signaling, translation, and transcription. They are also associated with 
cancer, and neurodegenerative diseases.  The tumor suppressor p53 contains several disordered 
regions, including the C-terminal negative regulatory domain (NRD).  In cancer the function of 
p53 has been shown to be repressed by S100B(ββ) binding to p53-NRD.  Binding of S100B(ββ) 
blocks acetylation and phosphorylation sites in the p53-NRD, which leads to tetramer 
dissociation and prevents p53 activation.  NMR studies have shown that p53-NRD binds 
S100B(ββ) in a stable α-helix conformation.  Interestingly, despite the well-converged and 
apparent rigid nature of the NMR structure ensemble, a majority of intermolecular NOEs used to 
calculate the NMR ensemble are very weak (≥6 Å). The final NMR structures also contains 
unsatisfied buried charged residues at the binding interface.  It’s plausible that the p53-
S100B(ββ) complex is more dynamic than previously believed.  The goal of the study is to 
determine the potential conformational heterogeneity in p53-S100B(ββ) complex using 
molecular modeling.  For this, five diverse structures were selected from the 40-member NMR 
ensemble.  For each initial conformation, we performed 100 ns molecular dynamic simulations 
in explicit solvent to explore the structure and dynamics of the p53-NRD in complex with 
S100B(ββ).  Several analytical tools were used to characterize the p53-NRD conformation, 
including root-mean squared deviation (RMSD), root-mean squared fluctuation (RMSF), and 
residue helicity.  The accuracy of the simulations was mainly assessed by comparing with 
experimental NOEs.  The results show that, even though the ensemble is heterogeneous it 
satisfies 82% of the experimental NOEs.  Clustering analysis further suggests that many 
conformational sub-states coexist for this complex, and individual clusters appear to satisfy only 
subsets of NOE distances.  Importantly, the buried surface analysis demonstrates that the 
heterogeneous ensemble generated from MD provides similar shielding of key residues, which 
include post-translational modification residues needed for p53 activation.  This study also 
demonstrates that atomistic simulations can provide important insights into structure and 
dynamics of IDPs for understanding their biological function. 
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Chapter 1 - Introduction of IDPs and Molecular Modeling 
 What Are IDPs? 
In the late 1990’s a new class of proteins began gaining recognition in the scientific 
community.  These proteins are now known as intrinsically disordered proteins (IDPs).  Under 
physiological conditions, IDPs lack stable tertiary structure (1). Despite their high degree of 
disorder, they are functionally active in the cell.  IDPs are highly abundant in nature, and one 
third of eukaryotic proteins are now known to contain intrinsically unstructured region spaces 
(2).  IDPs appear to be enriched in cell signaling, cancer associated proteins, Parkinson and 
Alzheimer disease, making them intriguing targets for therapeutic purposes (3) (Fig. 1.1).     
 
 
Figure 1.1 The percent of proteins containing disordered 
regions involved in cellular functions and diseases (4). 
 
Man functional benefits have been proposed for IDPs.  IDPs can bind their target proteins 
with low affinity and high specificity.  These proteins also display structural plasticity, which 
allows them to bind many different proteins.  Recently, IDPs have been shown to have 
heterogeneous conformations in the bound state (5,6).  The structure of IDPs are in constant flux 
between interconvertible conformations.  Some of these heterogeneous conformations may aid in 
the folding mechanism of IDPs.  This rapid exchange of heterogeneous conformations makes it 
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difficult to fully describe IDPs with a single structure (7).  In order to gain further mechanistic 
insights, IDPs need to be studied as conformational ensembles. 
 Sequence Characteristics of IDPs 
The inherit disorder observed in IDPs arises from their amino acid sequence.  IDPs are 
depleted in bulky hydrophobic residues, such as C, W, Y, F, V, L, and I, which are considered 
structure-inducing residues.  These proteins contain increased amounts of hydrophilic residues, 
such as M, K, R, S, Q, P, and E, which promote extended structures (8).  The reduced amount 
hydrophobic residues prevent IDPs from forming stable hydrophobic cores that are observed in 
structured proteins.  The lack of stable structure in IDPs gives rise to their promiscuous activity 
in the cell, being able to bind an array of functional proteins.   
 Structural Plasticity 
One of IDPs hallmarks is their structural plasticity.  Depending on the binding partner, 
IDPs may adopt diverse structures, involving subsets of amino acids.  p53 is a prime example for 
structural plasticity of IDPs.  The negative regulatory domain (NRD) of p53 has many binding 
partners.  The structure of p53 is known for four binding partners, Cyclin A2, S100B(ββ), 
Sirtuin, and CBP; which includes an extended, α-helix, β-stranded, or random coil structure, 
respectively (9) (Fig. 1.2). Structural plasticity of IDPs enables them to be involved in one-to-
many and many-to-one signaling; where one IDP can cause several different signaling cascades 
or an IDP can contain several signaling domains and bind one partner, respectively (4).   
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Figure 1.2 The structure of p53’s NRD bound to four 
different binding partners.  p53 adopts a different structure 
for each binding partner, α-helix, β-strand, extended 
structure, and random coil; when binding S100B(ββ), 
Sirtuin, Cyclin A2, and CBP, respectively (4). 
 
 Current Experimental Techniques for Studying IDPs  
There are several experimental techniques currently used in studies of IDPs. These 
methods include nuclear magnetic resonance (NMR), X-Ray crystallography, and circular 
dichroism (CD).  These are powerful structure determination techniques, but only give us a 
partial picture of IDP-protein interactions.  X-ray crystallography can resolve a static crystal 
structure of IDP complexes. These rigid structures are insufficient at describing dynamic 
properties of IDPs.  NMR studies have provided a wealth of structure and dynamic information 
about IDPs (7).  These studies give us stable structures, conformational ensembles, and many 
other observables.  These NMR ensembles can be very homogeneous.  For IDPs, these 
experimental observables are measured by averaging over large set of heterogeneous 
conformational sub-states.  The recovery of a heterogeneous ensemble from averaged properties 
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is a severely underdetermined problem.  The major problem with the current methods is that they 
cannot access or fully describe the heterogeneous conformational ensemble of IDPs.  A lack of 
knowledge of IDP conformational ensembles at the atomistic level has hindered the 
understanding of the binding and folding mechanism of IDPs.  
 Molecular Dynamic Investigation of IDPs 
Advancements in computing power and quality of biomolecular force fields have 
increased the accuracy of molecular dynamic (MD) simulations of large biomolecular systems.  
One of the major appeals of MD simulations is the atomistic insight into the structure-function 
relationship of biomarcomolecules, which may be difficult to obtain experimentally (10).  These 
insights gained from MD simulations have drawn many groups to employ this technique in their 
studies of IDPs (4,5,7,11-14).  MD simulations of IDPs can allow us to observe the 
heterogeneous conformational ensembles of IDPs and their functional role in the folding 
pathway and coupled binding-folding mechanism (7).   
A few examples of these studies include unbound residual structure, complex, along with 
coupled binding and folding studies.  There are many examples of MD studies examining the 
residual structure of IDPs.  The goal for these MD studies is to provide molecular detail of IDPs 
unbound residual structure.  The unbound structure of IDPs may have importance in their 
protein-protein interactions and folding mechanisms. One example is the study of unbound 
structure of KID and pKID (15).  In the study the authors look to determine the effect of 
phosphorylation of KID and how this effects binding to KIX (2).  The conformational substates 
have marginal differences between KID and pKID structure.  Interestingly, the study showed that 
phosphorylation of KID reduces the flexibility of a linker, which reduces the entropic cost for 
binding KIX (15).  This was not observed in NMR studies because conformational changes were 
not great enough to appear on the ensemble level (2).  Other studies of free IDPs have combined 
NMR experiments and MD simulations, such as Yoon et al. study of p21(16).  In this study the 
authors show that free p21 has residual structure, helical and extended conformation, that 
resembles complex with either calmodulin or proliferating cell nuclear antigen (16).  Studies of 
the nascent structure of free IDPs may give insights into their folding mechanisms. 
MD simulations are used to study the folding mechanisms of IDPs, but there is not an 
abundance of these studies due to the high cost for these simulations.  A study by Verkhivker et 
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al. used high-temperature and unfolding simulations to study the binding mechanism of p27 to 
Cdk2/Cyclin A (17).  The results of this study suggest that p27 binds through an induced folding 
mechanism.  This study pioneered the way for other MD studies of IDPs binding mechanism.  
Chen et al. ran 30 μs REX-MD simulations of NCBD-ACTR complex.  In this study, the authors 
showed that NCBD binds ACTR through a conformational selection mechanism (18,19).  Main 
of these studies use course grained proteins models and modified MD protocols, which reduce 
the cost of long time simulations and allow for greater conformational sampling.  These studies 
have given us insights into the binding and folding mechanism of IDPs. 
The two types of studies mentioned encompass many of the MD studies of IDPs.  
However, MD studies are also used to study the bound IDPs structure.  Bevan et al. used MD 
simulations to study the structure of p53-NRD bound to S100B(ββ) (11).  The results from this 
study show that p53-NRD adopts a stable α-helix.  Studies of bound IDPs is important for 
designing potential inhibitors.  Kriwacki et al. used MD simulations to study the structural 
dynamics of p27 bound to Cdk2 (20).  Results of this study showed that p27 has a mixture of 
helical and extended conformations.  The extended conformation segments are flexible, which 
the authors say is needed for p27’s signaling processes (20).  Many studies employ MD 
simulations to study the structure, folding and binding mechanisms of IDPs.  However, these 
studies would not be possible without a biomolecular force field.      
 Empirical Molecular Mechanics Force Fields 
The current biomolecular force fields use classical molecular mechanics treatment of 
atoms and their interactions (21). The potential energy function contains bonded terms (which 
include bonds, angles, dihedrals, and improper dihedrals energy terms), and a nonbonded terms 
(including Lennard-Jones potential and electrostatics): 
 
                
 
               
 
                                 
         
 
                 
   
   
   
 
  
  
   
   
   
 
 
  
    
     
                                      
 
          and    are bond, angle, dihedral, and improper dihedral force constants, respectively; 
d, θ, χ, and   are the bond length, angle, dihedral angle, and improper dihedral angle values of 
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the current confirmation and the corresponding zero subscript are the reference values (21).  The 
dihedral energy term contains multiplicity term, n, and the phase angle is represented by the δ 
variable (10).  The force constants and reference values in eq.1 are obtained from experimental 
data and quantum mechanical studies of small molecules or macromolecule fragments.  The final 
term is a combination of Lennard-Jones and Coulombic interactions between nonbonded atom 
pairs.      corresponds to the well depth of the Lennard-Jones potential,    
    is the distance 
where the potential equals zero, and     is the distance between atoms i and j.  The Coulombic 
term consist of the partial atomic charge,    and   , and    is the effective dielectric constant 
(21).  Nonbonded parameters for atom pairs are calculated based on the Lorentz-Berthelodt 
combination rules, in CHARMM22, the     values are calculated using the geometric mean 
between     values and     values,    
    values are calculated using the arithmetic mean between 
   
    values and    
    values.  The use of these combination rules may differ between force 
fields.  The potential energy, V(r), calculated from eq. 1 includes contributions from every bond, 
angle, and dihedral of the system.  This energy is for a single configuration (i.e. snapshot) of the 
system.  A series of snapshots are collected during simulations for subsequent system analysis.   
 
There are several general-purposed biomolecular force fields available, CHARMM22 
(22-24), AMBER99SB (25), OPLS-AA (26), and others.  The major differences between force 
fields are the force constants and equilibrium values.  Different biomolecular force fields are 
often optimized with different explicit water models. There are often systematic conformational 
biases, such as overstabilized helices and protein-protein interactions (1 & references therein).  
Some force fields, such as CHARMM22, have additional energy terms or use modified energy 
functions, in order to increase the accuracy of the force field (10).  Despite these efforts, the 
current force fields are not perfect (10). 
 What is MD? 
Molecular Dynamics (MD) is a sampling technique that solves Newton’s equation of 
motion with respect to time.  MD studies can give thermodynamic and kinetic information of 
protein complexes in solution.  This information allows us to study dynamic properties of protein 
structure and folding mechanisms (21).   MD simulations are expensive for two reasons.  First, 
MD uses a time step in the femtosecond time scale, which is limited by vibrational frequencies 
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of chemical bonds.  Secondly, for each step in time, the potential energy function is calculated 
for the biomolecular system.  Together, these factors render MD computationally expensive.   
The computational cost of energy calculation and time step has limited MD to select time scales.  
Recent developments in MD methodology has allowed many to simulate proteins into the micro- 
and millisecond time range, by reduce number of atoms in the system and/or improving 
sampling.   
 
Two primary challenges of atomistic simulations of IDPs are: force field accuracy and 
conformational sampling.  The current biomolecular force fields are not perfect, leading to 
inherent errors in protein simulations (10).  Besides force field problems MD faces another 
challenge.  MD simulations have problems with adequately sampling the conformational space, 
which reduces accuracy of calculated thermodynamic and kinetic properties of proteins.  
Inadequate sampling can arise from large entropic and enthalpic energy barriers that hinder 
spontaneous conformational transitions (21).  Adequate sampling of the conformational space 
often requires long time simulations (milliseconds to seconds timescale), which are 
computationally expensive or inaccessible in practice. MD simulations using explicit solvent 
have increased system sizes and atom number, which makes the energy calculation very 
expensive, due the added water molecules.  This increased cost from solvent limits the accessible 
time scales to nanosecond and low microsecond range.  Some these challenges can be overcome 
due to novel MD methodology and advancements in computer technology (21).   
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Chapter 2 - The Molecular Dynamic Study of p53-S100B(ββ) 
complex 
 Introduction 
Over the past couple of decades, a new class of functional proteins lacking a stable 
structure under physiological conditions has caught the attention of structural biochemists and 
other related fields.  These proteins are now known as intrinsically disordered proteins (IDPs) 
(12).  IDPs have several features of great interest to many.  IDPs bind their protein targets with 
low affinity and high specificity. The structural plasticity of IDPs allows them to bind many 
proteins with differing structures (1,8,12).  Importantly, IDPs have heterogeneous conformations, 
and cannot be fully described by a single structure (5,7).  Studies have shown that IDPs are 
involved in a wide range of biological function, such as cell signaling, proliferation, and 
differentiation (1,3,4,8,12).  IDPs have also been shown to be involved in cancer and other 
diseases (4).  Many groups across the globe are studying this intriguing newly recognized class 
of proteins for insights into their functions and therapeutic purposes (4,5,7,11-14). 
 
Due to heterogeneous conformations studying IDPs through conventional structural 
studies has proven difficult (7).  Conventional experimental methods only measure average 
conformational properties, subsequently suppressing IDPs conformational ensembles that are 
important in IDP function (5,7).  Advances in computing technology and quality of force fields 
have made molecular dynamics a powerful tool for studying IDPs.  Molecular dynamic 
simulations in principle allow us to observe the conformational evolution of IDPs with respect to 
time, giving more complete pictures of these proteins. 
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Figure 2.1 The Domains of the Tumor Suppressor p53 (20) 
 
One IDP that has gained a lot of attention over the years is the tumor suppressor p53, due 
to its potential use in cancer therapy.  In normal cells, p53 is present in low levels and serves as a 
hub for signaling transduction.  p53 is activated in response to stress, which causes levels of 
active p53 to increase rapidly to prevent cell cycling, apoptosis, and repair DNA (27,28).  Many 
studies have shown that the function of p53 is altered in cancer cells, due to mutations of p53 or 
inhibition by regulatory proteins (3,29,30).  p53 is a modular protein that binds DNA as a 
tetramer, each subunit is comprised of the following domains.  The central domain of p53 is a 
folded DNA binding domain.  p53 contains two disorder domains at the termini.  The C-terminus 
is known as the negative regulatory domain (NRD) and the N-terminus is known as the 
transactivation domain (TAD) (4,8) (Fig. 2.1).  These two regions serve as signaling domains; 
the N-terminus actives transcription and the C-terminus has regulatory functions. The NRD 
contains phosphorylation and acetylation sites, which serve to control oligomerization, 
transcriptional activation, and DNA binding.  This region has many binding partners but only 
four complex structures are known (see Fig. 1.2).    One of these complexes is between p53-NRD 
and S100B(ββ). 
   
The normal function of S100B(ββ) is negative regulation of p53.  When S100B(ββ) binds 
p53-NRD, it blocks several post-translational modification sites, which inhibits the function of 
p53 (29-31).  S100B(ββ) binding p53-NRD leads to dissociation of the p53 tetramer.  This is 
needed in normal cells to allow further cellular proliferation if required.  However, S100B(ββ) 
levels are elevated in cancer cells.  This increase severely reduces functional p53, allowing the 
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cells to proliferate without control.  This interaction is of great interest to the biomedical 
community as a possible cancer therapy target that could restore functional p53 levels. 
 
Previous NMR studies show that p53-NRD adopts a stable helix when binding 
S100B(ββ) (PDB ID: 1DT7) (32).  Despite the apparent well converged and rigid ensemble of 
NMR structures, there are several features that raise questions about its stable structure.  A 
majority of the assigned intermolecular NOEs from NMR fall in the weak range (6-7 Å) (32), 
which is suggestive of a heterogeneous conformational state (7).  Many of the NMR structures 
have buried charged residues and bulky side-chains lying across the helix to satisfy buried NOEs 
(Fig. 4).  These characteristics from this NMR study lead us to believe that p53-NRD may 
sample a heterogeneous conformational ensemble when bound to S100B(ββ).   
 
In this study we use extensive all-atom simulations to study the potential heterogeneity in 
the p53-S100B(ββ) complex.  The NMR structures from previous study are used as initial 
conformations.  Two well-known force fields are used for the simulations of p53-S100B(ββ) 
complex.  The simulated ensemble satisfies a vast majority (82%) of the experimental NOEs.  
However, the ensemble is heterogeneous particularly in the p53 moiety.   Clustering analysis of 
the simulated ensemble suggest that many conformations are sampled by bound p53, satisfying 
different sub-sets of intermolecular NOE restraints. 
 Methods 
 Explicit solvent simulation 
The NMR ensemble consists of 40 NMR structures (PDB ID: 1DT7) and each contains two p53-
NRD (369-388) in complex with a S100B(ββ) dimer (32).  Five diverse structures were selected 
to initiate the independent simulations to facilitate conformational sampling (see Fig. 2.2).  These 
conformers were identified based on mutual root mean square deviation (RMSD).  The first 
NMR structure serves as a reference of the NMR ensemble, along with initial conformation for 
the first CHARMM (22-24,33) and GROMACS (34,35) simulation.  The other conformers are 
the 21st, 23rd, 30th and 31st models in the NMR ensemble. 
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Figure 2.2 Five models from the NMR structure ensemble that were used as initial 
conformations for CHARMM simulations.  From top left to right, the model 
numbers are 1st, 21nd, 23rd, 30th, and 31st.  Structure 1 was also used in the Gromacs 
simulation.  The residues shown are R379, L383, and F385. 
 
The initial conformations require several modifications before proceeding with the 
simulations.  The p53 segment consists of residues 369-388; N-terminal residues (369-373) are 
in an extended conformation and appear to have little involvement in the interaction.  These 
residues are truncated to reduce size (and computational cost) of the simulations.  The five 
models are solvated in a ~70×60×50 Å water box containing ~9011 TIP3P waters; overlapping 
waters are removed.  Six calcium ions were added to neutralize the system.  
  
The five systems are simulated in CHARMM (24,33).  All molecules are described by 
CHARMM22/CMAP all-atom force field. Each system is equilibrated for 50 ps under NPT 
conditions, followed by a 100 ns NPT simulation.  Weak harmonic positional restraints were 
placed on S100B(ββ) backbone to prevent large conformational deviations or dissociation of the 
S100B(ββ) dimer.   SHAKE algorithm was used to constrain the bonds to allow for a two 
femtosecond (fs) time step (36).  Particle Mesh Ewald (PME) was used to treat long-range 
electrostatics (37), and van der Waals (vdW) interactions use a 15.0 Å cutoff.  For validation, 
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model 1 was simulated in GROMACS using AMBER99SB (25) following the same protocol as 
in CHARMM simulations. 
 Structural Analysis 
All analysis was performed using CHARMM, Multiscale Modeling Tools for Structural 
Biology (MMTSB) toolset (38), and/or in house scripts, unless otherwise noted.  NOE like 
distances were calculated from the trajectories for direct comparison with experimental values.  
For this, coordinates of all the atoms involved in the NOE assignments were first extracted from 
simulation. For NOEs that involve more than a single pair of atoms, the NOE distances were 
calculated using the r-6 summation (39),  
           
 
   
  
 
 
 
 
   (2) 
where rij is the distance between atoms and t is time.  The time-averaged NOE distances are 
calculated as:  
               
     
 
 
   (3) 
 Clustering 
The last 60 ns of each 100 ns independent production simulations were included to 
extract an ensemble of p53-S100B(ββ).  Each simulated model contains a dimer complex, and is 
seperated into two independent monomer conformations.  When these five simulations are 
combined, there is a total of 600 ns of production sampling of the monomer complex.  A 
conformation was extracted every 100 ps, generating a conformational ensemble of 6000 p53-
S100B(ββ) monomer complex structures.  This ensemble was clustered using the MMTSB 
toolset (38),  using k-mean algorithm, where members of the cluster are assigned based on 
distances to the cluster center.  The distance is based on p53 Cα RMSD, calculated by first 
aligning the complex using the backbone atoms of S100B(ββ).  The calculated RMSD values as 
defined reflect both internal conformational or binding mode changes of p53.  Several cutoff 
radii were tested in clustering; with a final value of 5 Å that appeared to give clusters with the 
cleanest separation.  NOE and helicity analysis was performed for each of the ten most populated 
clusters identified.  These clusters presumably represent sub-states sampled by p53 when bound 
to S100B(ββ). 
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 Results and Discussion 
 Structural and NMR evidence for fuzziness in the p53/S100B(ββ) complex 
NMR structures of p53/S100B(ββ) have several features that suggest possible 
conformational heterogeneity.  As mentioned in the introduction, these features include 
unsatisfied buried charges, bulky residues and large number of weak intermolecular NOEs.  For 
example, R379 of p53-NRD is buried within the hydrophobic binding site of S100B(ββ) (Fig. 
2.3).  These residues prefer hydrophilic environments, which are not observed in the NMR 
structures.  We propose that these residues may adapt their conformation to a suitable 
environment. 
 
Figure 2.3 Monomer of p53-S100B(ββ) complex extracted from the 
NMR structure (PDB ID: 1DT7).  Three key residues are shown 
above F385, R379, and L383.  L383 is the proposed anchoring 
residue from NMR studies.  R379 is an example of an unsatisfied 
buried charged residue observed in the NMR structure.  The other 
residue of interest is F385, which is seen to lay across the helix in 
the NMR structure, but is involved in several intermolecular NOEs 
to S100B(ββ). 
 
If the structure of p53 is stable in complex with S100B(ββ), then we would except to 
observe a larger number of strong NOEs.  However, a only a set of very weak NOEs were 
assigned for this complex (see Table 2.1).  Several of the experimental intermolecular NOEs 
involve buried atom pairs that are not satisfied by these stable NMR structures.  These 
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observations lead us to believe that p53 is heterogeneous and samples a series of conformations 
that satisfy sub-sets of intermolecular NOEs. 
 Stability of the p53/S100B(ββ) complex 
During simulation, large changes are observed in conformation and binding pose of p53-
NRD.  As shown in Fig. 2.4 A, The Cα RMSD rapidly increases to ~5.5 Å in simulation. These 
large deviations in Cα RMSD are correlated with a change in both conformation of p53-NRD and 
its relative position with respect to S100B(ββ) (Fig. 2.5). 
 
 
Figure 2.4 (A) Cα RMSD of p53 from the five simulated models.  Model 1 (red), 
Model 21 (green), Model 23 (blue), Model 30 (pink), Model 31 (cyan). (B) Residue 
helicity plot shows four of the simulated models and experimental helicity (cyan); 
several models had similar helicity values to the red line.  
 
The residue helicity of simulations shows a reduction in the helical content of p53 (Fig. 2.4B).  
Greater conformational changes in p53-NRD are observed in models with large RMSDs.  The 
large conformational changes are correlated to previously unsatisfied charges (R379) become 
solvent exposed.  However, models that retain their helicity display changes in the binding 
position of p53-NRD.  The large RMSDs and changes in residue helicity suggest that p53-NRD 
is heterogeneous.   
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Figure 2.5 Final snapshots of the five independent simulations; top left 
to right, simulated models 1st, 21st, 23rd, 30th, and 31st. 
 
Previous simulations have shown that p53 remains very stable (11), and many of the 
changes we observed in our simulations are absent in these simulations.  To confirm that our 
findings were not an artifact of the CHARMM22/CMAP force field, the system was also 
simulated using the AMBER99SB force field in GROMOS.  The GROMOS simulation also 
showed a loss in helicity along with large RMSDs (Fig. 2.6). 
  
 
Figure 2.6 (A) Cα RMSD of p53 and S100B(ββ), black and red respectively.  (B) 
Final snapshot of p53-S100B(ββ) from GROMACS simulations. 
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The GROMACS simulation of p53-S100B(ββ) complex confirms our results from the 
CHARMM22/CMAP simulations.  The stable nature of p53 observed in previous simulations 
may arise from differences in initial conditions or duration of simulation, which may suppress 
the dynamic features of p53 that are observed in this study.  Taken together, the current extensive 
simulations clearly support that p53-NRD remains highly dynamic when bound to S100B(ββ). 
 NOE analysis of simulated models 
In order to examine how realistic the simulated ensemble is, we back calculated NOE-
like distances and compared them with experimental values.  The NOE-like distances obtained 
from simulation underwent summation and time averaging (see Methods).  As shown in Table 
2.1, the majority of NOEs calculated from the five independent simulations are satisfied, with 
only 6 or 18% of the 33 intermolecular NOEs violated.  The violated NOEs involve previously 
buried charged residues and/or bulky side chains that become solvent exposed.  Figure 2.7 and 
2.8 show the histograms and time-traces of a few representative NOE distances.  There is 
significant heterogeneity in the instantaneous NOE distances, rnoe(t) as defined by Eq. 2, 
frequently fluctuating above the experimental upper bound.  Note that these NOE-average 
distances can be misleading when comparing to NOE distances of the individual models. These 
values obtained from r-6 averaging of the whole ensemble emphasize contributions from 
conformers with shorter distances. 
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Figure 2.7 Histograms of six NOEs, two for each of these residues R379, L383, and 
F385, from the five independent simulations.  The same color code is used as in Fig. 2 
A.  The black dashed line represents the experimental NOE upper bound. 
 
Table 2.1 The first column contains the atom pairs involved in intermolecular NOEs.  Groups 
of atoms are denoted by HX*.  Second column has the upper bound from experiment.  Third 
column is the r-6 summation of the ten monomers from simulations.  The final column is the 
violation between simulation and experiment.  Zeroes correspond to satisfied NOEs. 
NOE Exp. Upper Bound (Å) Sim. Distance (Å) Violation (Å) 
Q375 HB* - E51 HG*  6 7 1 
R379 HB* - K48 HG* 5 7 2 
R379 HD* - V52 HG2*  6 3 0 
L383 HD* - L3 HD*  6 6.2 0 
L383 HD* - V52 HG2*  6 3.1 0 
L383 HD* - V56 HG*  5 2.2 0 
L383 HD* - M7 HE*  5 6.2 1.2 
L383 HD* - V77 HG2*  6 7.3 1.3 
L383 HD* - M79 HE*  3.3 3.1 0 
L383 HB* - M79 HE*  5 4 0 
L383 HD* - V80 HG2* 4.2 2.9 0 
L383 HD* - V80 HG1* 5 3.4 0 
L383 HD* - T82 HG2* 6 7.1 1.1 
L383 HB* - A83 HB*  5 3.1 0 
L383 HD* - A83 HB*  5 4.7 0 
M384 HE* - L44 HD*  6 3.4 0 
M384 HB* - K55 HG*  6 4.5 0 
M384 HG* - V56 HG*  6 2.3 0 
M384 HE* - V56 HG*  6 2.8 0 
F385 HZ - L44 HD*  6 3 0 
F385 HE* - M79 HE*  6 4.9 0 
F385 HZ - M79 HE*  6 6.5 0 
F385 HE* - V80 HG2*  6 3 0 
F385 HZ - V80 HG2*  6 4.3 0 
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F385 HD* - V80 HG1*  6 5 0 
F385 HE* - A83 HB*  5 4.1 0 
F385 HZ - A83 HB*  6 3.3 0 
K386 HD* L44 HD*  6 8.4 2.4 
K386 HD* - T82 HG2*  5 3.4 0 
K386 HG* - T82 HG2*  6 4.4 0 
T387 HG* - K55 HG*  5 4.2 0 
E388 HG* - M79 HE*  5 4.6 0 
E388 HG* - T82 HG2*  6 4.2 0 
 
 
 
Figure 2.8 Time averaged NOE distances over the final 60ns of simulations; these are 
the same NOEs from the histograms above.  The black line is the experimental upper 
bound.  
 
The ability of the heterogeneous ensemble derived from extensive MD simulations to 
reproduce experimental NOEs strongly supports our hypothesis that p53 is dynamic when bound 
to S100B(ββ).     
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Figure 2.9 Solvent accessible surface area (SASA) of p53 residues 
from simulation and experiment.  The red bars are the average SASA 
of 40 NMR structures with error bars.  The green bars are the average 
SASA of the 5 simulations with error bars. 
 
More importantly, can this heterogeneous ensemble still inhibit activation of p53?  To 
answer this we calculated the buried solvent accessible surface area (SASA) of p53.  As shown 
in Figure 2.9, the SASA profiles between experimental and simulated ensembles are very 
similar.  There are several residues in simulation (R379 and K386) that have increased SASAs 
compared to experiment.  These changes are caused by the residues flip out of the binding site 
during simulation to satisfy their unpaired charges.  However, key residues that need to be block 
from post-translational modifications (Phosphorylation sites: S376 and T377, Acetylation sites: 
R379 and K386) are similarly buried.  This suggests that despite the dynamic nature of p53 in 
simulation, the inhibition of p53 is maintained. 
 Clustering analysis 
Data collected from the five independent simulations show that the structure of p53 is 
highly dynamic when interacting with S100B(ββ).  NOE analysis of simulation showed varying 
sets of satisfied NOEs over the simulations.  From these results, we suspect that the complex 
samples a distinct set of conformational sub-states, which could give rise to different NOE 
subsets.  The ensemble of sub-states together samples all intermolecular NOEs assigned 
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experimentally.  Ensemble clustering is used to identify the largest sampled sub-states.  The 
highest populated sub-states are shown in figure 2.10.   
 
Figure 2.10 Top ranked cluster conformations with NMR structure for 
reference; yellow trace is S100B(ββ) and purple cartoon p53.  The 
value next to the rank is the percent of structures occupying that 
cluster. 
 
Many of the proposed sub-states are highly helical; exceptions to this are clusters 3 and 8, 
which have coiled conformations at the termini (Fig. 2.10).  The largest difference between sub-
states is the binding poses of p53 with respect to S100B(ββ).  These features appear to arise from 
the increased solvation of R379 and K386 side-chains.  Interestingly, p53 segments pivot around 
L383 (Fig. 2.10).  We have also analyzed NOE violation for each cluster.  As shown in figure 13, 
individual clusters satisfy different NOE subsets.  All of the sub-states satisfy a majority of the 
L383 NOEs, which are important for anchoring of p53.  The clusters also violate many of the 
NOEs involving charged terminal residues (R379, E388, K386, and Q375) (Fig. 2.11), which 
have the most dynamic residual structure.  These differences in NOE subsets arise from 
conformation and positional differences in p53.  When these sub-states are observed as an 
ensemble, all experimental NOE distances are satisfied.  This shows that p53 samples a 
heterogeneous ensemble of many sub-states that fulfill the intermolecular NOEs, and inhibit the 
activation of p53. 
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Figure 2.11 NOE violations of the top ten highest populated 
clusters.  Intermolecular NOEs are shown on the y-axis.  The green 
blocks are satisfied and red are violated. 
 
 Conclusions 
We use extensive MD simulations to study the p53-S100B(ββ) complex, in which p53 
was previously thought to adopt a stable alpha-helix.  However, the calculated structures and 
NOEs provide evidence that p53-NRD may not have a stable structure.  Extensive MD 
simulations of the p53-S100B(ββ) complex show that p53-NRD is highly dynamic, while 
satisfying 82% of the experimental NOEs.  We propose a conformational ensemble of p53-NRD 
that fulfills the intermolecular NOEs.  These sub-states still block key post-translational 
modification sites needed for p53 activation.  In this study, we show that p53 is heterogeneous, 
which samples an ensemble of conformations that still prevent p53 activation.  We also show 
MD is a good technique for studying the structure and dynamics of IDPs, further understanding 
the biological function of these newly recognized proteins. 
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